Clinical Trials
25 trialsNCT06466798 2026-01-08
Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies
The University of Texas Health Science Center, Houston
Phase 1 Withdrawn
NCT06770257 2025-06-03
Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Withdrawn
NCT05766514 2025-04-22
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
University of Florida
Phase 2 Withdrawn
NCT05823480 2024-09-19
Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS
City of Hope Medical Center
Phase 1 Withdrawn
NCT05367401 2024-04-11
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Novartis
Phase 1/2 Withdrawn
NCT05720988 2024-03-08
Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT06085638 2024-03-07
Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT06180863 2023-12-26
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients
Yale University
Phase 2 Withdrawn
NCT03932318 2023-07-20
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
Actinium Pharmaceuticals
Phase 1/2 Withdrawn
NCT03745352 2023-06-27
Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT04230564 2023-06-07
Acute Myeloid Leukemia Real World Treatment Patterns
Pfizer
Withdrawn
NCT04264806 2022-05-20
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
Janssen Research & Development, LLC
Phase 2 Withdrawn
NCT04648826 2021-12-17
Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT04296214 2021-07-09
Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
Grupo Cooperativo de HemopatÃas Malignas
Withdrawn
NCT04128020 2020-10-12
Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
Big Ten Cancer Research Consortium
Phase 1 Withdrawn
NCT03612739 2019-10-29
EPITHINK
Celyad Oncology SA
Phase 1 Withdrawn
NCT03699384 2019-02-20
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Withdrawn
NCT03182894 2018-08-28
Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer
University of Pittsburgh
Phase 1/2 Withdrawn
NCT02204020 2018-03-30
UPCI 13-165
University of Pittsburgh
Phase 2 Withdrawn
NCT02829840 2017-06-02
Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00842582 2016-11-02
Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer
Loyola University
Phase 1 Withdrawn
NCT02303782 2016-09-01
A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2 Withdrawn
NCT02701673 2016-05-04
Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT01067274 2015-12-30
ALFA-0703
Acute Leukemia French Association
Phase 3 Withdrawn
NCT01292083 2014-02-06
Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery
University of Southern California
Phase NA Withdrawn